Enbioco인바이오
352940 · KOSDAQ · ₩352940 · 인바이오
₩1,920▲ ₩36 (1.91%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 39.0% | 34.8% | 33.1% | 21.3% | 19.2% | 32.8% |
| Operating margin | 3.4% | 2.7% | 3.9% | −9.9% | −14.0% | 3.4% |
| Net margin | 1.6% | 3.0% | 1.8% | −18.5% | −10.1% | 15.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +6.6% | −4.8% | +4.8% | −0.6% | +2.3% | — |
| Operating income growth | +34.1% | −34.7% | +141.9% | +29.8% | −525.9% | — |
| Net income growth | −43.0% | +56.0% | +110.2% | −82.9% | −165.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 1.3% | 2.4% | 1.6% | −14.4% | −7.1% | 10.5% |
| Return on assets | 0.8% | 1.5% | 1.0% | −8.2% | −3.9% | 5.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 77.2% | 63.2% | 63.8% | 62.8% | 87.9% | 81.5% |
| Net debt to equity | 47.7% | 24.5% | 31.4% | 22.7% | 22.6% | −5.4% |
| Current ratio | 172.0% | 167.6% | 184.4% | 185.8% | 174.3% | 184.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Enbioco / 인바이오 / 352940 / KRX:352940
Source: KRX statistical information